help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-1298
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/3/1136    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saner-Amigh, K.
Right arrow Articles by Rainey, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saner-Amigh, K.
Right arrow Articles by Rainey, W. E.
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Cardiovascular Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 3 1136-1142
Copyright © 2006 by The Endocrine Society

Elevated Expression of Luteinizing Hormone Receptor in Aldosterone-Producing Adenomas

Karla Saner-Amigh, Bobbie A. Mayhew, Franco Mantero, Francesca Schiavi, Perrin C. White, Chalama V. Rao and William E. Rainey

Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology (K.S.-A., B.A.M.), and Department of Pediatrics (P.C.W.), University of Texas Southwestern Medical Center, Dallas, Texas 75390-9032; Department of Medical and Surgery Sciences (F.M., F.S.), University of Padua, 35128 Padua, Italy; Department of Obstetrics and Gynecology and Women’s Health (C.V.R.), University of Louisville Health Sciences Center, Louisville, Kentucky 40292; and Department of Physiology (W.E.R.), Medical College of Georgia, Augusta, Georgia 30912

Address all correspondence and requests for reprints to: William E. Rainey, Ph.D., Department of Physiology, Medical College of Georgia, 1120 15th Street, Augusta, Georgia 30912. E-mail: wrainey{at}mcg.edu.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Context: The mechanisms driving steroid production in aldosterone-producing adenomas (APAs) are poorly defined. However, previous studies have shown that steroid production in some cortisol-producing adenomas is regulated by aberrant expression of G protein-coupled receptors. Aberrant adrenal expression of LH receptors has been shown to cause Cushing’s syndrome, but the role of LH receptors in Conn’s disease (hyperaldosteronism) has not been studied.

Objective: The objective of the study was to determine whether APAs express elevated LH receptor, compared with normal adrenal (NA).

Design: Pools of RNA from NA and APAs were hybridized to oligonucleotide microarrays. Data were confirmed using real-time RT-PCR analysis of RNA derived from NA (n = 20) and APAs (n = 18). Aldosterone synthase transcription was studied in H295R adrenocortical cells transfected with an LH receptor expression construct and reporter constructs prepared from CYP11B2 5'-flanking DNA.

Patients: The patient population consisted of 20 normal control adrenals and 18 adenomas from patients with APAs.

Main Outcome Measure: Regulation of CYP11B2 gene expression by aberrant LH receptor expression in aldosterone-producing adrenal adenoma was measured.

Results: LH/choriogonadotropin receptor gene and CYP11B2 are indicated as having greater than 25-fold expression in one pool of APA mRNA samples over NA using microarray analysis. Real-time RT-PCR analyses indicated that one APA sample (APA-LH receptor) exhibited more than 2400-fold elevation in LH receptor expression over NA. Examination of LH receptor mRNA levels in 18 independent APA samples indicated elevated expression in nine samples when compared with NA. In H295R cells transfected with LH receptor, LH treatment caused a concentration-dependent increase in CYP11B2 reporter activity.

Conclusion: LH receptor expression is elevated in many APAs, which makes LH a potential cause of the excessive production of aldosterone in a subset of these adrenal tumors.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
THE HUMAN LH receptor is a member of the rhodopsin/ß2-adrenergic receptor subfamily of G protein-coupled receptors (1). It is able to independently activate two known signaling pathways. The more consistently used pathway is through coupling to GS, the G protein responsible for activation of numerous adenylyl cyclase isozymes (2). However, studies in a variety of cell types indicate that LH receptor can also activate phospholipase C, which in turn increases phosphatidylinositol turnover and elevates intracellular Ca2+ levels (3, 4, 5, 6).

The LH receptor is expressed primarily in gonadal cells including Leydig cells in testes and differentiated granulosa cells, luteal cells, and theca cells in the ovary. In each of these cell types, LH has been shown to play a critical role in both the regulation of steroid hormone production as well as the expression of steroid-metabolizing enzymes. LH receptor is also expressed in a number of nongonadal tissues including human uterus (7), fallopian tubes (8), prostate (9), and breast cancer biopsies (10), although its role in these tissues is unclear. Interestingly, expression of LH receptor has been documented in the adrenal gland using immunohistochemistry (11). Yet a role for LH in the regulation of normal human adrenal cortisol or dehydroepiandrosterone production has not been supported by in vivo studies or using cells in culture (12, 13).

Aberrant expression of LH receptor in adrenal tumors has been shown to cause some cases of ACTH-independent Cushing’s syndrome (14, 15, 16). However, the role of LH and the aberrant expression of LH receptor in Conn’s syndrome (primary aldosteronism) have not been studied. Herein we present novel findings that suggest that expression of LH receptor is elevated in more than half of aldosterone-producing adenomas (APA). In addition, we demonstrate in an adrenocortical cell model transfected with LH receptor that LH can increase the transcription of aldosterone synthase, which is required for the final reaction in aldosterone synthesis. Together these findings suggest that defining the role of aberrant expression of LH receptor in primary aldosteronism warrants further clinical study.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Subjects and tissues

Normal human adult and fetal adrenals, APAs, ovarian follicles, and corpus luteum tissues were obtained through the Cooperative Human Tissue Network (Philadelphia, PA), Clontech (Palo Alto, CA), the Obstetrics and Gynecology Department of University of Texas Southwestern and/or the University of Padua. The normal adrenal samples came from autopsies performed no more than 6 h after death from causes unrelated to adrenal function. The use of these tissues was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center (Dallas, TX).

Microarray analysis

RNA from an adult adrenal (n = 1) and a pool of APAs (n = 3) were hybridized to an Affymetrix human HG-U133 + 2 oligonucleotide microarray set containing 54,675 probe sets representing approximately 40,500 independent human genes. The arrays were scanned at high resolution using an Affymetrix GeneChip Scanner 3000 located at the University of Texas Southwestern Microarray Core Facility. Results were analyzed using GeneSpring (version 6.1 software; Silicon Genetics, Redwood City, CA) to identify differences in expression of G protein-coupled receptors between normal adult adrenal and APAs.

RNA extraction, cDNA synthesis, and real-time RT-PCR

Total RNA was extracted from tissues (17), and purity and integrity of the RNA were checked spectroscopically. Deoxyribonuclease I (2 µg; Ambion, Inc., Austin, TX)-treated total RNA was reverse transcribed using the high-capacity cDNA archive kit (Applied Biosystems, Foster City, CA) following the manufacturer’s recommendations and stored at –80 C. Primers for the amplification of the target sequences were based on published sequences for human LH receptor and human CYP11B2. The primer set used was designed to target the 5' region of LH receptor: forward, 5'-GCCATCAAGAGAAACATTTGTCAA-3' and reverse, 5'-TTTCTAAAAGCACAGCAGTGGCT-3'. The primer/probe set for CYP11B2 consisted of: forward, 5'-GGCAGAGGCAGAGATGCTG-3', reverse, 5'-CTTGAGTTAGTGTCTCCACCAGGA-3', and probe, 5'-CTGCACCACGTGCTGAAGCACT-3'. PCRs were performed using the ABI Prism 7000 sequence detection system (Applied Biosystems) with a total volume of 30 µl per reaction following the reaction parameters recommended by the manufacturer. For LH receptor the 30 µl total volume consisted of SYBR Green universal PCR master mix (x2) (Applied Biosystems), 50 nM of each primer, and 5 µl of each first-strand cDNA sample. CYP11B2 reaction mix consisted of TaqMan ribosomal RNA reagent (Applied Biosystems), 100 nM of primer/probe mix, and 5 µl of each first-strand cDNA sample. Negative controls contained water instead of first-strand cDNA.

Cell culture, transfection assays, and plasmid constructs

H295R human adrenocortical tumor cells were cultured in DMEM/Ham’s F12 medium supplemented with 10% cosmic calf serum (Hyclone, Logan, UT) and antibiotics. For transfection experiments, cells were subcultured onto 12-well dishes at a density of 400,000 cells/well. Transfections were carried out using the transfection reagent Transfast (Promega, Madison, WI) according to manufacturer’s directions for 6 h. To normalize luciferase activity, cells were cotransfected with 50 ng/well of Renilla plasmid (Promega). After recovery of the cells for 20–24 h, cells were treated with human LH (Sigma, St. Louis, MO) for 6 h before being lysed and assayed for activity using the dual-luciferase assay system (Promega). The 5'-flanking DNA from the human CYP11B2 gene has been previously described (18). The expression construct human LH receptor, encoding the full-length human LH receptor, was a gift from Dr. Ilpo Huhtaniemi (University of Turku, Turku, Finland) (19).

Immunohistochemistry (IHC)

IHC was performed by an avidin immunoperoxidase method using a polyclonal LH/human chorionic gonadotropin (hCG) receptor antibody raised against a human receptor N-terminus amino acid sequence of 15–36 and affinity purified (20). The sections were incubated overnight at 4 C with a 1:200 dilution of the receptor antibody. For the procedural control, the receptor antibody was preabsorbed with excess receptor peptide.

Western analysis

Western analysis was performed by homogenizing tissue in 25 mM HEPES buffer (pH 7.4) containing 10 µg/ml leupeptin and aprotinin and 50 µg/ml 4-(2-aminoethyl)-benzenesulfonyl-fluoride. Thirty-microgram protein aliquots were dissolved in loading buffer [125 mM Tris-HCl (pH 6.8) containing 4% sodium dodecyl sulfate and 20% glycerol] and separated by 8% discontinuous SDS-PAGE under reducing conditions. The separated proteins were electroblotted onto Immobilon P membranes. After blocking the nonspecific binding sites with 5% nonfat dry milk in 5 mM Tris-HCl (pH 7.4) containing 136 mM NaCl and 0.1% Tween 20, the blots were incubated overnight at 4 C with a 1:800 dilution of the LH receptor antibody and washed three times for 10 min each with 5 mM Tris-HCl (pH 7.4) containing 136 mM NaCl and 0.1% Tween 20 buffer. The washed blots were incubated again for 1 h at room temperature with a 1:1000 dilution of horseradish peroxidase-labeled secondary antibody, and then the binding of the LH receptor was detected by an enhanced chemiluminescence detection system.

Statistical analysis

Data were analyzed and compared with control values using the Mann-Whitney rank sum test with the SigmaStat 3.0 software package (SPSS, Chicago, IL). Treatments were considered significantly different when P < 0.05.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Microarray analysis was performed using a pool of three APAs and compared with RNA from normal adult adrenal to examine alterations in expression patterns of G protein-coupled receptors. The results (Fig. 1Go) clearly indicate that the aldosterone synthase gene (CYP11B2) as well as the LH receptor were expressed at levels more than 25 times higher in the APA pool than the normal adrenal. Other receptor mRNAs with expression levels more than 25-fold higher in the APA pool than the normal adrenal were the CD47 antigen receptor (56-fold higher), the putative purinergic receptor FKSG79 (29-fold), and the cholinergic receptor CHRM1 (29-fold). Due to the established role of LH receptor in the regulation of ovarian and testicular steroid production, we focused on this G protein-coupled receptor. To confirm the data of the microarray, real-time RT-PCR analyses were performed on the normal adrenal and APA samples used for microarray as well as positive controls for LH receptor expression that included corpora lutea (n = 9) and ovarian follicles (n = 10) and a negative control consisting of whole fetal adrenal (n = 5) for comparison. Analyses were performed with a set of primers that targeted the 5' region (Fig. 2Go) and 3' region (data not shown) of the LH receptor mRNA. Similar results were obtained using both primer pair sets, and therefore, only the data from the analysis of the 5' region of the mRNA are shown. In Fig. 2AGo, the normal adrenal sample used in the microarray analysis had an average value of approximately 0.006 attomoles of LH receptor mRNA per microgram of 18s mRNA, compared with the wide range seen with the three APA samples from the microarray, which ranged from 0.0182 to 14.5 attomoles/µg 18s mRNA. The LH receptor expression levels in fetal adrenal were similar to those seen in normal adrenal (0.008 attomoles/µg 18s). As shown in Fig. 2BGo, although quite variable, the overall expression of LH receptor in corpus luteum was relatively high (3.02 attomoles/µg 18s) with slightly lower values in the ovarian follicles (0.76 attomoles/µg 18s mRNA). A single adrenal adenoma sample that we termed APA-LH receptor exhibited expression levels for LH receptor 2400-fold higher than that seen in normal adrenals (14.5 attomoles/µg 18s).


Figure 1
View larger version (26K):
[in this window]
[in a new window]
  		FIG. 1. Microarray analysis comparing the mRNA expression patterns in human normal adrenal and APAs. Each dot represents a unique sequence with a total of approximately 545 transcripts of G protein-coupled receptors examined from these oligonucleotide arrays. Dots within the parallel lines represent mRNAs with less than 25-fold difference in expression. LH receptor and CYP11B2 are indicated as having greater than 25-fold expression in adenoma samples over normal adrenals. LHCGR, LH/choriogonadotropin receptor gene.

 

Figure 2
View larger version (15K):
[in this window]
[in a new window]
  		FIG. 2. Confirmation of microarray data. Quantification of LH receptor mRNA levels in samples used in our microarray as well as positive and negative controls [normal adrenal (n = 1), APAs (n = 3), corpus luteum (n = 9), ovarian follicle (n = 10), and fetal adrenal (n = 5)] was done using primers directed to the 5' end of the mRNA as described in Subjects and Methods. Data represent the mean ± SEM of each group of samples and are expressed as attomoles per microgram 18s mRNA. A, APA1, APA2, normal adrenal, and fetal adrenal with expression values ranging from 0.006 to 0.026 attomoles LH receptor mRNA per microgram 18s mRNA. B, APA-LH receptor (APA-LHR), corpus luteum, and ovarian follicle with expression values ranging from 0.76 to 14.5 attomoles LH receptor mRNA per microgram 18s mRNA.

 
Immunohistochemical data in the APA-LH receptor sample supported the real-time data. As previously demonstrated (21), LH receptor shows intense staining in the corpus luteum (Fig. 3AGo), compared with preabsorbed control (Fig. 3BGo). The APA sample showed groups of intensely staining cells throughout the tumor sample (Fig. 3CGo). Western analysis confirmed levels of LH receptor expression in APA-LH receptor that were as high as that seen in corpus luteum (Fig. 3DGo).


Figure 3
View larger version (96K):
[in this window]
[in a new window]
  		FIG. 3. Immunohistochemical analysis of LH receptor expression in corpus luteum (A) and the APA-expressing high LH receptor (APA-LHR) (C). B, Corpus luteum stained with a preabsorbed control. D, Western analysis indicating elevated levels of LH receptor (LHR) in both corpus luteum and the APA-LHR sample.

 
Further analysis of the CYP11B2 and LH receptor expression levels in normal adrenals (n = 20) and APAs (n = 18) indicated that, as expected, all APA samples expressed levels of the CYP11B2 gene that were outside the range seen in normal adrenals (Fig. 4AGo). Surprisingly, 50% (nine of 18) of the APAs examined also exhibited elevated levels of LH receptor, whereas only one of the normal samples was 2 SD above normal LH receptor expression. Using linear regression analysis, there is a correlation between LH receptor and CYP11B2 expression (r = 0.49, P = 0.0256) in the APA samples we studied. In contrast, neither the microarray nor real-time analyses of the ACTH receptor mRNA indicated any difference in expression between normal adrenals and APAs (data not shown).


Figure 4
View larger version (18K):
[in this window]
[in a new window]
  		FIG. 4. A, Vertical point scatterplot comparing aldosterone synthase gene (CYP11B2) expression in normal adrenal vs. APA samples. Sixteen of 20 normal adrenal samples (80%) fell within normal range (defined as ± 2 SD from the mean of the normal adrenals) vs. none of the APA samples (0%). The difference in the median values between the two groups is statistically significant (P ≤ 0.001). B, Vertical point scatterplot comparing LH receptor expression in normal adrenal vs. APA samples. Nineteen of 20 normal adrenal samples (95%) fell within normal range vs. only nine of 18 APA samples (50%). The difference in the median values between the two groups is statistically significant (P ≤ 0.001).

 
To determine whether LH treatment is able to increase expression of CYP11B2, transient transfections were performed in H295R adrenocortical cells with expression vectors for LH receptor and reporter constructs for the CYP11B2 promoter. As shown in Fig. 5Go, LH was able to mediate CYP11B2 promoter activity in the presence of LH receptor with a maximal 25-fold induction of the promoter over basal with a dose of 50 ng/ml, indicating that LH receptor levels in the adrenal can drive aldosterone production in the presence of LH. No effect of LH was seen in cells that were not transfected with LH receptor expression vectors (data not shown).


Figure 5
View larger version (16K):
[in this window]
[in a new window]
  		FIG. 5. Concentration-dependent effects of LH on CYP11B2 reporter gene activity in H295R cells cotransfected with LH receptor (LHR)-containing vectors. H295R cells were transfected with luciferase reporter constructs containing the CYP11B2 promoter construct at a concentration of 1 µg/well. Cells were cotransfected with LH receptor expression plasmid at a concentration of 0.3 µg/well and incubated overnight at 37 C. Cells were then treated with the indicated amounts of LH or angiotensin II (100 nM) for 6 h and then lysed and assayed for luciferase activity. Data were normalized to cotransfected ß-galactosidase, and data shown are expressed as fold induction over basal reporter plus LH receptor. Results represent the mean ± SEM of data from at least three independent experiments each performed in triplicate.

 

   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
Aldosterone plays a major role in salt and water homeostasis and is thus under tight control of the renin-angiotensin system. Primary aldosteronism results from elevated secretion of aldosterone, often in the form of an APA. Patients with primary aldosteronism arising from APAs are often resistant to medical antihypertensive therapies and require a unilateral adrenalectomy to restore a normotensive state. Generally, APAs produce aldosterone in a renin-independent manner and no longer stop aldosterone production under the low renin conditions seen in these patients. The mechanisms that maintain aldosterone production in APAs are ill defined.

A number of studies have demonstrated that cortisol-producing adenomas can be under the control of aberrantly expressed membrane receptors. Food-dependent hypercortisolism is a rare form of Cushing’s syndrome that can occur when gastric inhibitory polypeptide receptor (GIPR) is overexpressed in cases of either bilateral macronodular hyperplasia or an adrenal tumor (22). This causes an abnormal cortisol responsiveness to gastric inhibitory polypeptide, which increases after oral intake of glucose. Recent data indicate that GIPR expression is also present in adrenals with nonfood-dependent Cushing’s syndrome but not normal adrenals (23). In addition, it is postulated that chronic ACTH stimulation may cause up-regulation of GIPR (23). Data from our microarray analyses indicate that there were several other G protein-coupled receptors that had elevated mRNA levels in APA arrays, compared with normal adrenals. Serotonin 5HT4R expression levels were at least 3-fold higher in APA samples, compared with normal adrenal, although this has not been confirmed via real-time RT-PCR in individual samples at this point (data not shown). 5HT4R expression levels in three Cushing’s adenoma microarray sets indicate slightly lower-than-normal adrenal expression levels. The major difference in G protein-coupled receptor expression was noted for the LH receptor, although several other genes including CD47 antigen receptor, the putative purinergic receptor FKSG79, and the cholinergic receptor CHRM1 also illustrated expression levels greater than 25-fold over normal in our representative microarray shown in Fig. 1Go.

LH-responsive Cushing’s syndrome has been described in a number of cases (16, 24, 25, 26) In at least one case (16), Cushing’s syndrome was thought to have developed during pregnancy due to the high levels of circulating hCG, which binds and activates LH receptors. In this particular patient the adrenal disease spontaneously abated after delivery, presumably due to the associated drop in circulating hCG although this hypothesis was not formulated until the patient was seen with similar symptoms at menopause. High LH levels, as seen in postmenopausal women, can also lead to Cushing’s syndrome if the adrenal aberrantly expresses LH receptors (16, 27, 28). Due to the significant number of cases reported with LH regulation of Cushing’s syndrome as a result of aberrant adrenal expression of LH receptor, some clinical algorithms include an LH stimulation test (24).

The potential role of LH in regulation of Conn’s syndrome is far less understood; however, if a role exists, it could be speculated that men (high circulating LH) as well as pregnant (high circulating hCG) or postmenopausal women (high circulating LH) might be likely candidates for LH-regulated hyperaldosteronism. Certainly primary aldosteronism follows a variable course in pregnancy. Normally, aldosterone levels increase in pregnancy 4-fold by 8 wk gestation and continue to increase reaching a 10-fold increase by term. However, this increase is due to increased renin and angiotensin II levels (29). In some women with primary hyperaldosteronism, hypertension improves with pregnancy, and this is thought to be due to an increase in plasma progesterone or other steroids that competitively inhibit the effects of aldosterone on its receptor (30, 31, 32). However, hypertension, hypokalemia, low plasma renin activity, and very high aldosterone levels can appear in the course of pregnancy, suggesting a primary hyperaldosteronism and an adrenal adenoma is sometimes detected (33, 34). In some pregnancies with aldosterone producing adenomas, surgery is required to remove the adenoma (35, 36), whereas in others hypertension is controlled adequately by therapy, and removal of the tumor can occur in the postpartum period (34). No specific information is available on the prevalence of primary aldosteronism in menopause.

The current study used microarray technology to compare expression profiles of G protein-coupled receptors between APAs and normal adrenal glands. This leads to the discovery of an LH-mediated APA with high expression levels of LH receptor taken from a 37-yr-old male patient who presented with uncontrollable hypertension. This patient became normotensive after tumor removal. We verified LH receptor mRNA expression in APA and normal adrenals using real-time RT-PCR. Whereas expression at the level seen in corpus luteum appears rare for APA (one of 18), the expression of LH receptor is elevated above normal adrenal in 50% of APA samples. Previous studies of LH receptor expression in the human adrenal has been limited to IHC and in situ hybridization or nonquantitative RT-PCR for mRNA (11, 37). Immunohistochemical analysis suggested that LH receptor was expressed in the adrenal cortex with higher signal in the inner reticularis zone (11).

An early report suggested that LH/hCG regulated human fetal adrenal steroid production (38). This was an attractive hypothesis because circulating levels of hCG are extremely high in the fetus and apparently correlate with the extremely active fetal adrenal. However, the effects of purified LH or hCG on human fetal adrenal cell steroidogenesis was not confirmed by others (13, 39). Indeed, using the real-time RT-PCR method developed for the present project the expression of fetal adrenal LH receptor was no different from the very low level found in normal adult adrenals, further decreasing the likelihood of a role for hCG in the regulation of the fetal adrenal gland. To better examine the effects of LH/hCG on human adrenal steroid production, a recent in vivo study used GnRH analogs to down-regulate LH production by the pituitary and then examine effects of exogenously administered hCG on circulating adrenal steroids in both healthy premenopausal and oophorectomized postmenopausal women (12). In premenopausal women, hCG increased the serum concentrations of partially or exclusively ovarian steroids such as 17-hydroxyprogesterone, androstenedione, testosterone, and estradiol but had no effect on steroids of exclusively adrenal origin such as dehydroepiandrosterone, dehydroepiandrosterone sulfate, or cortisol. Postmenopausal women were concomitantly treated with estrogen replacement therapy when hCG was administered in an effort to avoid potential LH receptor down-regulation due to chronic high levels of endogenous gonadotrophins. As expected, basal serum concentrations of ovarian steroids were much lower than those of premenopausal women, and hCG treatment did not increase these levels. Nor were adrenal steroid levels increased in these women after treatment with hCG. However, modest increases in dehydroepiandrosterone sulfate secretion with high doses of LH have been observed in human adrenocortical H295R carcinoma cells (40). Thus, the exact role of LH in the function of the normal adrenal remains uncertain.

Nevertheless, it appears likely from previous studies on cortisol-producing adenomas and our current report on APAs that aberrant expression of the LH receptor plays a role in adrenal disease. It is still unclear why aberrant expression of the LH receptor would cause hypercortisolism in some cases and hyperaldosteronism in others. For that reason we examined the effects of LH on the transcriptional activity of CYP11B2. The final step in aldosterone synthesis requires CYP11B2, and no alternative pathways for the synthesis of aldosterone have been found. CYP11B2 is normally regulated by angiotensin II and potassium through the elevation of intracellular calcium and activation of calcium signaling pathways (41, 42, 43). We found that LH increased the promoter activity of CYP11B2, suggesting that in vivo LH could act in adenomas to increase the capacity to produce aldosterone.

In summary, microarray analysis of APAs vs. normal adrenals indicated elevated expression of the LH receptor in the APA pool over normal adrenal. Further confirmation of LH receptor in APA was substantiated by real-time RT-PCR, IHC, and Western blot analysis. We have also demonstrated that LH can increase the transcriptional activity of the aldosterone synthase gene. Analysis of a larger pool of APAs and normal adrenals indicates that elevated expression of LH receptor may be common in APAs. The role of LH as a regulator of certain cases of primary aldosteronism warrants further clinical study.


   Acknowledgments
 
We thank Professor Ilpo Huhtaniemi (Imperial College of London) for the LH expression vector.


   Footnotes
 
First Published Online December 6, 2005

Abbreviations: APA, Aldosterone-producing adenoma; GIPR, gastric inhibitory polypeptide receptor; hCG, human chorionic gonadotropin; IHC, immunohistochemistry.

This work was supported by awards (DK43140) from the National Institutes of Health (to W.E.R.).

The authors have no conflict of interest.

Received June 10, 2005.

Accepted November 30, 2005.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Ascoli M, Fanelli F, Segaloff DL 2002 The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev 23:141–174[Abstract/Free Full Text]
  2. Herrlich A, Kuhn B, Grosse R, Schmid A, Schultz G, Gudermann T 1996 Involvement of Gs and Gi proteins in dual coupling of the luteinizing hormone receptor to adenylyl cyclase and phospholipase C. J Biol Chem 271:16764–16772[Abstract/Free Full Text]
  3. Gilchrist RL, Ryu KS, Ji I, Ji TH 1996 The luteinizing hormone/chorionic gonadotropin receptor has distinct transmembrane conductors for cAMP and inositol phosphate signals. J Biol Chem 271:19283–19287[Abstract/Free Full Text]
  4. Gudermann T, Birnbaumer M, Birnbaumer L 1992 Evidence for dual coupling of the murine luteinizing hormone receptor to adenylyl cyclase and phosphoinositide breakdown and Ca2+ mobilization. Studies with the cloned murine luteinizing hormone receptor expressed in L cells. J Biol Chem 267:4479–4488[Abstract/Free Full Text]
  5. Gudermann T, Nichols C, Levy FO, Birnbaumer M, Birnbaumer L 1992 Ca2+ mobilization by the LH receptor expressed in Xenopus oocytes independent of 3',5'-cyclic adenosine monophosphate formation: evidence for parallel activation of two signaling pathways. Mol Endocrinol 6:272–278[Abstract]
  6. Rajagopalan-Gupta RM, Lamm ML, Mukherjee S, Rasenick MM, Hunzicker-Dunn M 1998 Luteinizing hormone/choriogonadotropin receptor-mediated activation of heterotrimeric guanine nucleotide binding proteins in ovarian follicular membranes. Endocrinology 139:4547–4555[Abstract/Free Full Text]
  7. Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N, Luborsky JL 1990 The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 70:421–430[Abstract]
  8. Lei ZM, Reshef E, Rao V 1992 The expression of human chorionic gonadotropin/luteinizing hormone receptors in human endometrial and myometrial blood vessels. J Clin Endocrinol Metab 75:651–659[Abstract]
  9. Rao CV 2001 An overview of the past, present, and future of nongonadal LH/hCG actions in reproductive biology and medicine. Semin Reprod Med 19:7–17[CrossRef][Medline]
  10. Meduri G, Charnaux N, Loosfelt H, Jolivet A, Spyratos F, Brailly S, Milgrom E 1997 Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res 57:857–864[Abstract/Free Full Text]
  11. Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA, Rao CV 1996 Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. J Clin Endocrinol Metab 81:2397–2400[Abstract]
  12. Piltonen T, Koivunen R, Morin-Papunen L, Ruokonen A, Huhtaniemi IT, Tapanainen JS 2002 Ovarian and adrenal steroid production: regulatory role of LH/HCG. Hum Reprod 17:620–624[Abstract/Free Full Text]
  13. Fujieda K, Faiman C, Reyes FI, Winter JS 1981 The control of steroidogenesis by human fetal adrenal cells in tissue culture. III. The effects of various hormonal peptides. J Clin Endocrinol Metab 53:690–693[Abstract]
  14. Bugalho MJ, Li X, Rao CV, Soares J, Sobrinho LG 2000 Presence of a Gs {alpha} mutation in an adrenal tumor expressing LH/hCG receptors and clinically associated with Cushing’s syndrome. Gynecol Endocrinol 14:50–54[Medline]
  15. Dall’Asta C, Ballare E, Mantovani G, Ambrosi B, Spada A, Barbetta L, Colombo P, Travaglini P, Loli P, Beck-Peccoz P 2004 Assessing the presence of abnormal regulation of cortisol secretion by membrane hormone receptors: in vivo and in vitro studies in patients with functioning and non-functioning adrenal adenoma. Horm Metab Res 36:578–583[CrossRef][Medline]
  16. Lacroix A, Hamet P, Boutin JM 1999 Leuprolide acetate therapy in luteinizing hormone-dependent Cushing’s syndrome. N Engl J Med 341:1577–1581[Free Full Text]
  17. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ 1979 Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294–5299[CrossRef][Medline]
  18. Bassett MH, Zhang Y, White PC, Rainey WE 2000 Regulation of human CYP11B2 and CYP11B1: comparing the role of the common CRE/Ad1 element. Endocr Res 26:941–951[Medline]
  19. Zhang FP, Kero J, Huhtaniemi I 1998 The unique exon 10 of the human luteinizing hormone receptor is necessary for expression of the receptor protein at the plasma membrane in the human luteinizing hormone receptor, but deleterious when inserted into the human follicle-stimulating hormone receptor. Mol Cell Endocrinol 142:165–174[CrossRef][Medline]
  20. Carlson HE, Kane P, Lei ZM, Li X, Rao CV 2004 Presence of luteinizing hormone/human chorionic gonadotropin receptors in male breast tissues. J Clin Endocrinol Metab 89:4119–4123[Abstract/Free Full Text]
  21. Bukovsky A, Caudle MR, Keenan JA, Wimalasena J, Upadhyaya NB, Van Meter SE 1995 Is corpus luteum regression an immune-mediated event? Localization of immune system components and luteinizing hormone receptor in human corpora lutea. Biol Reprod 53:1373–1384[Abstract]
  22. N'Diaye N, Tremblay J, Hamet P, De Herder WW, Lacroix A 1998 Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing’s syndrome. J Clin Endocrinol Metab 83:2781–2785[Abstract/Free Full Text]
  23. Swords FM, Aylwin S, Perry L, Arola J, Grossman AB, Monson JP, Clark AJ 2005 The aberrant expression of the gastric inhibitory polypeptide (GIP) receptor in adrenal hyperplasia: does chronic adrenocorticotropin exposure stimulate up-regulation of GIP receptors in Cushing’s disease? J Clin Endocrinol Metab 90:3009–3016[Abstract/Free Full Text]
  24. Lacroix A, Ndiaye N, Tremblay J, Hamet P 2001 Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr Rev 22:75–110[Abstract/Free Full Text]
  25. Leinonen P, Ranta T, Siegberg R, Pelkonen R, Heikkila P, Kahri A 1991 Testosterone-secreting virilizing adrenal adenoma with human chorionic gonadotrophin receptors and 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 34:31–35[Medline]
  26. Feelders RA, Lamberts SW, Hofland LJ, van Koetsveld PM, Verhoef-Post M, Themmen AP, de Jong FH, Bonjer HJ, Clark AJ, van der Lely AJ, De Herder WW 2003 Luteinizing hormone (LH)-responsive Cushing’s syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. J Clin Endocrinol Metab 88:230–237[Abstract/Free Full Text]
  27. Bovenberg SA, Pieters GF, Hofland LJ, Hermus AR 2004 Leuprolide acetate therapy in LH-dependent Cushing’s syndrome: in vivo and in vitro observations. Neth J Med 62:456–458[Medline]
  28. Mijnhout GS, Danner SA, van de Goot FR, van Dam EW 2004 Macronodular adrenocortical hyperplasia in a postmenopausal woman. Neth J Med 62:454–455[Medline]
  29. Wilson M, Morganti AA, Zervoudakis I, Letcher RL, Romney BM, Von Oeyon P, Papera S, Sealey JE, Laragh JH 1980 Blood pressure, the renin-aldosterone system and sex steroids throughout normal pregnancy. Am J Med 68:97–104[CrossRef][Medline]
  30. Gordon RD, Tunny TJ 1982 Aldosterone-producing-adenoma (A-P-A): effect of pregnancy. Clin Exp Hypertens A 4:1685–1693[Medline]
  31. Matsumoto J, Miyake H, Isozaki T, Koshino T, Araki T 2000 Primary aldosteronism in pregnancy. J Nippon Med Sch 67:275–279[Medline]
  32. Murakami T, Watanabe OE, Tanaka Y, Yamamoto M 2000 High blood pressure lowered by pregnancy. Lancet 356:1980
  33. Baron F, Sprauve ME, Huddleston JF, Fisher AJ 1995 Diagnosis and surgical treatment of primary aldosteronism in pregnancy: a case report. Obstet Gynecol 86:644–645[Abstract]
  34. Lotgering FK, Derkx FM, Wallenburg HC 1986 Primary hyperaldosteronism in pregnancy. Am J Obstet Gynecol 155:986–988[Medline]
  35. Aboud E, De Swiet M, Gordon H 1995 Primary aldosteronism in pregnancy—should it be treated surgically? Ir J Med Sci 164:279–280[Medline]
  36. Solomon CG, Thiet M, Moore Jr F, Seely EW 1996 Primary hyperaldosteronism in pregnancy. A case report. J Reprod Med 41:255–258[Medline]
  37. Bachelot A, Meduri G, Massin N, Misrahi M, Kuttenn F, Touraine P 2005 Ovarian steroidogenesis and serum androgen levels in patients with premature ovarian failure. J Clin Endocrinol Metab 90:2391–2396[Abstract/Free Full Text]
  38. Seron-Ferre M, Lawrence CC, Jaffe RB 1978 Role of hCG in regulation of the fetal zone of the human fetal adrenal gland. J Clin Endocrinol Metab 46:834–837[Abstract]
  39. Mason JI, Hemsell PG, Korte K 1983 Steroidogenesis in dispersed cells of human fetal adrenal. J Clin Endocrinol Metab 56:1057–1062[Abstract]
  40. Rao C, Zhou XL, Lei ZM 2004 Functional luteinizing hormone/chorionic gonadotropin receptors in human adrenal cortical H295R cells. Biol Reprod 71:579–587[Abstract/Free Full Text]
  41. Bassett MH, White PC, Rainey WE 2004 The regulation of aldosterone synthase expression. Mol Cell Endocrinol 217:67–74[CrossRef][Medline]
  42. Condon JC, Pezzi V, Drummond BM, Yin S, Rainey WE 2002 Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase. Endocrinology 143:3651–3657[Abstract/Free Full Text]
  43. Pezzi V, Clyne CD, Ando S, Mathis JM, Rainey WE 1997 Ca2+-regulated expression of aldosterone synthase is mediated by calmodulin and calmodulin-dependent protein kinases. Endocrinology 138:835–838[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
P. de Cremoux, D. Rosenberg, J. Goussard, C. Bremont-Weil, F. Tissier, C. Tran-Perennou, L. Groussin, X. Bertagna, J. Bertherat, and M.-L. Raffin-Sanson
Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease
Endocr. Relat. Cancer, June 1, 2008; 15(2): 465 - 474.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Vuorenoja, A. Rivero-Muller, A. J Ziecik, I. Huhtaniemi, J. Toppari, and N. A Rahman
Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin {beta} conjugate
Endocr. Relat. Cancer, June 1, 2008; 15(2): 635 - 648.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
Y. Nakamura, S. Aoki, Yewei Xing, H. Sasano, and W. E. Rainey
Metastin Stimulates Aldosterone Synthesis in Human Adrenal Cells
Reproductive Sciences, December 1, 2007; 14(8): 836 - 845.
[Abstract] [PDF]

Home page
 J EndocrinolHome page
P. Ye, B. Mariniello, F. Mantero, H. Shibata, and W. E Rainey
G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism
J. Endocrinol., October 1, 2007; 195(1): 39 - 48.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Lindeberg, K. Carlstrom, O. Ritvos, and O. Hovatta
Gonadotrophin stimulation of non-luteinized granulosa cells increases steroid production and the expression of enzymes involved in estrogen and progesterone synthesis
Hum. Reprod., February 1, 2007; 22(2): 401 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. D. Looyenga and G. D. Hammer
Origin and Identity of Adrenocortical Tumors in Inhibin Knockout Mice: Implications for Cellular Plasticity in the Adrenal Cortex
Mol. Endocrinol., November 1, 2006; 20(11): 2848 - 2863.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/3/1136    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saner-Amigh, K.
Right arrow Articles by Rainey, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saner-Amigh, K.
Right arrow Articles by Rainey, W. E.
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Cardiovascular Endocrinology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals